PL4048230T3 - Doustne kompozycje gliptiny i sposób ich wytwarzania - Google Patents
Doustne kompozycje gliptiny i sposób ich wytwarzaniaInfo
- Publication number
- PL4048230T3 PL4048230T3 PL20790187.7T PL20790187T PL4048230T3 PL 4048230 T3 PL4048230 T3 PL 4048230T3 PL 20790187 T PL20790187 T PL 20790187T PL 4048230 T3 PL4048230 T3 PL 4048230T3
- Authority
- PL
- Poland
- Prior art keywords
- gliptin
- oral
- compositions
- preparation
- oral gliptin
- Prior art date
Links
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19205219.9A EP3811930A1 (en) | 2019-10-24 | 2019-10-24 | Oral gliptin compositions and method for preparation thereof |
| PCT/EP2020/079945 WO2021078964A1 (en) | 2019-10-24 | 2020-10-23 | Oral gliptin compositions and method for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4048230T3 true PL4048230T3 (pl) | 2024-03-11 |
Family
ID=68344633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20790187.7T PL4048230T3 (pl) | 2019-10-24 | 2020-10-23 | Doustne kompozycje gliptiny i sposób ich wytwarzania |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11944621B2 (pl) |
| EP (2) | EP3811930A1 (pl) |
| ES (1) | ES2961549T3 (pl) |
| PL (1) | PL4048230T3 (pl) |
| WO (1) | WO2021078964A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113476400A (zh) * | 2021-08-02 | 2021-10-08 | 成都倍特药业股份有限公司 | 一种丙戊酸钠口服溶液及其制备方法 |
| AU2023277704A1 (en) * | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| CN116440074B (zh) * | 2023-05-26 | 2024-02-20 | 浙江高跖医药科技股份有限公司 | 一种氯化钾口服制剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2433090A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| ES2339112T3 (es) | 2002-08-21 | 2010-05-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos. |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| CA2633167A1 (en) * | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
| EP2691083B1 (en) * | 2011-03-29 | 2017-08-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition of sitagliptin |
| WO2015044880A1 (en) | 2013-09-25 | 2015-04-02 | Ranbaxy Laboratories Limited | Oral liquid pharmaceutical composition of a dpp-iv inhibitor |
| US20160287583A1 (en) * | 2013-11-18 | 2016-10-06 | Ranbaxy Laboratories Limited | Oral dispersible composition of a dpp-iv inhibitor |
| WO2015144825A1 (en) * | 2014-03-27 | 2015-10-01 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Oral liquid pharmaceutical solution of gabapentin |
-
2019
- 2019-10-24 EP EP19205219.9A patent/EP3811930A1/en not_active Withdrawn
-
2020
- 2020-10-23 WO PCT/EP2020/079945 patent/WO2021078964A1/en not_active Ceased
- 2020-10-23 EP EP20790187.7A patent/EP4048230B1/en active Active
- 2020-10-23 PL PL20790187.7T patent/PL4048230T3/pl unknown
- 2020-10-23 US US17/771,387 patent/US11944621B2/en active Active
- 2020-10-23 ES ES20790187T patent/ES2961549T3/es active Active
-
2024
- 2024-02-26 US US18/587,175 patent/US12295953B2/en active Active
-
2025
- 2025-04-25 US US19/189,609 patent/US20250302828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4048230A1 (en) | 2022-08-31 |
| US12295953B2 (en) | 2025-05-13 |
| EP3811930A1 (en) | 2021-04-28 |
| US20250302828A1 (en) | 2025-10-02 |
| ES2961549T3 (es) | 2024-03-12 |
| US20240285619A1 (en) | 2024-08-29 |
| EP4048230B1 (en) | 2023-10-04 |
| WO2021078964A1 (en) | 2021-04-29 |
| US11944621B2 (en) | 2024-04-02 |
| US20220387427A1 (en) | 2022-12-08 |
| EP4048230C0 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287248A (en) | Methods and preparations for editing RN" A | |
| GB2605276B (en) | Methods and compositions for genomic integration | |
| IL290544A (en) | Methods of manufacturing improved arganoid preparations | |
| EP3938505A4 (en) | COMPOSITIONS AND METHODS FOR SEQUENCING THE NEXT GENERATION | |
| IL290833A (en) | Preparations and methods for cll1 modification | |
| IL288024A (en) | Methods and preparations for the prevention of type 1 diabetes | |
| GB202017593D0 (en) | Compositions and methods and uses relating thereto | |
| EP3826673A4 (en) | COMPOSITIONS AND METHODS FOR IMAGING | |
| IL290469A (en) | Oral pharmaceutical preparation | |
| IL292682A (en) | Formulation of x842 for oral administration | |
| IL282100A (en) | Methods and compounds for treating oral mucositis | |
| PL4048230T3 (pl) | Doustne kompozycje gliptiny i sposób ich wytwarzania | |
| IL286587A (en) | Preparations of d-methyrosine and methods for their preparation | |
| IL290325A (en) | Biopharmaceutical preparations and related methods | |
| EP3813842A4 (en) | PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF | |
| ZA202203368B (en) | Immunogenic compositions against enteric diseases and methods for its preparation thereof | |
| IL283593A (en) | Bernaflam oral preparations | |
| GB2579687B (en) | Composition and method | |
| SG11202104346YA (en) | Compositions and methods for nhej-mediated genome editing | |
| ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof | |
| SG11202108262VA (en) | Bacterialcidal methods and compositions | |
| GB201914777D0 (en) | Composition and method | |
| EP3787415A4 (en) | Oral compositions and methods for affecting mammalian offspring | |
| HK40050800A (en) | Methods and compositions for treating oral mucositis | |
| GB202211117D0 (en) | Compositions and methods for non-immunogenecity |